November Emerging Medical Technologies Report

Table of Contents

BRIEF TECHNOLOGY DESCRIPTIONS FOR COMPANIES COVERED

•1-Next-generation, minimally-invasive glaucoma drainage implant and 2-Intraocular lens (IOL) for microincision surgery
•A medical device for sternal protection during cardiac surgery; helps decrease bleeding from the divided sternum which results in increased morbidity and complication rates, and reduce trauma to and fractures of the sternum from the sternal retractor
•A minimally invasive rotator cuff implant intended to provide a new treatment option for patients with small tears and improve the treatment of patients with large tears
•A non-invasive sleep hypoglycemia alert system
•A novel treatment for Dry Eye; extremely small device is placed adjacent to the lacrimal gland and stimulates endogenous tear secretion, thus providing symptomatic lubrication as well as protecting the cornea from erosion, punctate keratopathy, ulceration, neovascularization, and possible scarring
•A small, ergonomic surgical vessel sealing system for use in general surgery (primarily laparoscopic surgeries) where access to surgical sites with conventionally sized technology has been limited; used with a low-power bipolar generator
•Adeno-associated virus (AAV) gene therapy technology for the treatment of orphan muscle diseases
•An access wire system that enables quick access to challenging peripheral vascular anatomy, in carotid and renal interventions, interventional oncology and endovascular aneurysm repair
•An autologous percutaneous arteriovenous fistula (AVF) creation device for hemodialysis access
•An inflatable balloon retractor for use in laparoscopic procedures, to effectively and gently retract the abdominal organs such as the intestines during surgery
•An off-the-shelf, cell-free hyaline cartilage regeneration product for use in repairing chondral and osteochondral defects in the weight-bearing joints such as the knee, hip, and shoulder; coral scaffold-based technology is implanted via a minimally invasive, single-step arthroscopic procedure
•Bio-artificial cartilage resurfacing product to treat osteoarthritis (OA), with several advantages over existing alternatives
•Biocompatible products for bone and soft tissue regeneration, fulfilling needs in the orthopedic, spine and dental markets
•Biomaterials technology for use in tissue sealing and hemostasis
•Cancer diagnostics and screening tests for prostate, breast and ovarian cancer
•Cell therapy technology for the treatment of diabetes
•Computer-assisted system for faster, more accurate, and simpler joint replacement surgery
•Device that provides heart failure (HF) patients with regular monitoring of fluid status within their home setting, thereby providing physicians with improved information with which to manage the disease
•Devices for the interventional treatment of cardiovascular disease
•Diagnostic tests for lung, breast, prostate and colorectal cancer, among other illnesses, that help individuals monitor their health status and detect diseases early by measuring the body's unique response (its "immunosignature") to a given disease or disease state, rather than measuring the pathogen directly
•Disease-modifying drugs for Alzheimer's disease (AD) and other neurodegenerative disorders
•Handheld breast self-examination scanning device that utilizes very low-level light (photons) to create a digital map of the breast with GPS-like precision
•Highly accurate computer-based visual cognitive test to help physicians predict Alzheimer's disease (AD) three to six years before symptoms appear
•High-quality, biodegradable biomaterial products for use in tendon regeneration, soft tissue repair, spinal cord repair, neuroregeneration, and cardiovascular applications including stents; company also provides a design, development and fabrication service for customized biomaterial solutions for medical device, pharmaceutical and other manufacturers
•Implantable neuromodulator for the spinal cord to advance the rehabilitation and recovery of individuals suffering with paralysis
•Implantable surgical reconstruction products to be used in general surgery applications
•Implantable system that delivers electrical pulses at night, during sleep, to restore a more normal breathing pattern and improve cardiovascular health in patients with Central Sleep Apnea (CSA)
•Implantable, bio-degradable, collagen-based drug delivery system for the sustained-release of glaucoma medication
•Innovative solutions for vascular interventions
•Line of fast-acting, over-the-counter (OTC) medications, formulated as a dissolvable powder, for on-demand relief from headaches, aches and pains, heartburn, allergies, and upset stomach
•Low cost, portable digital joint replacement surgical guidance instrument to calculate and display real-time measurements of implant position and alignment, with an initial focus on hip replacement
•Low-cost flow cytometer cell sorters that analyze and sort without damaging the cell
•Medical grade hydration powder as a safe and better-tasting alternative to conventional oral rehydration system (ORS) and pediatric formulas
•Microscopy technology integrated in optoelectronic modules that attach to a research-grade optical microscope, for real-time 3D topography
•Minimally invasive surgical retractor system for use in micro-endoscopic discectomies; incorporates fiber optic lighting, translucent retractor blades, full medial access, and an expandable field of view
•Minimally invasive, blood-based diagnostics for the early detection and staging of Alzheimer's and Parkinson's diseases, via the detection of disease-specific autoantibodies; long-term goal is to develop a single protein microarray that can simultaneously screen for many diseases in one blood test that uses a single drop of blood
•Minimally invasive, catheter-based devices, with an initial focus on delivering an alternative to current ablation and drug therapies for atrial fibrillation (AF)
•Next-generation electrophysiology and atrial fibrillation (Afib) mapping and ablation devices, as an alternative to current catheter ablation technologies
•Next-generation RNA interference (RNAi)-based therapeutics to reach previously undruggable intracellular disease targets, including cancer
•Non-contact and continuous heartbeat and respiratory monitoring device
•Non-invasive biophotonics-based system which consists of a primary multi-LED light device and a topical photo converter gel for use in dentistry, dermatology, and chronic wound treatment
•Non-invasive lung function imaging devices that allow clinicians to rapidly identify pulmonary-related issues across a broad patient population; the technology captures functional images of the lungs by analyzing chest wall movement, and translates this data into pulmonary function outputs
•Non-invasive, intrauterine device for monitoring vital signs for fetuses of obese mothers, starting with fetal heart rate (FHR), using proprietary light-based technology; FHR is displayed on existing bedside equipment
•Non-invasive, non-imaging system that enables physicians to identify the onset of cardiovascular disease at the earliest stages of development by measuring endothelial dysfunction
•Ocular surface technology that speeds recovery and immediately returns significant functional vision to patients after LASIK or PRK
•Optical imaging technology that permits rapid, detailed assessment of the vasculature for low-cost diagnostic purposes
•Orally stable peptides for diseases that are currently being addressed only by injectable biologics
•Orthopedic healing and biologics technologies, including bone stimulation devices and osteoarthritis injection treatments
•Osmotically-driven, self-expanding device inserted at the ostium of the maxillary sinus, to restore functional sinus drainage and ventilation while minimizing patient discomfort in the treatment of chronic sinusitis
•Personalized health electronics technology; a vital sign monitor that analyzes, tracks and trends vital signs such as temperature, respiratory rate, oximetry, ECG, systolic blood pressure and diastolic blood pressure, in 10 seconds
•Personalized stem cell therapy using adipose-derived stem cells, as well as somatic cells (e.g., chondrocytes, fibroblasts); also researching the use of autologous growth factors for use in reconstructive medicine and tissue repair, including cartilage and skin regeneration, and bio-ophthalmics
•Production platform to generate unit doses of molecular imaging drugs for positron emission tomography (PET) at the point-of-use, in a way that is more convenient, versatile, and significantly less expensive than current methods available
•Proteomic platform that can accurately measure more than 1,100 proteins in a broad concentration range with minimal volume requirements
•Regenerative amniotic tissue-based products for use in the ophthalmology, optometry, musculoskeletal, and wound care markets
•Revolutionary nanosensing technology that will deliver earlier disease diagnosis, improve therapy programs, and better manage and prevent chronic diseases
•Scar-free laparoscopic surgery tools that enable surgery with extremely small incisions, leaving no visible scars and enabling assembly of complex tools inside the patient; requires minimal surgeon retraining
•Small molecule drugs that combine the best aspects of both irreversible inhibition and reversible non-covalent target inhibition
•The first continuous, noninvasive respiratory monitor for use in anesthesia/operating room, post-op recovery, procedural sedation and intensive care hospital settings
•Thrombectomy device that can treat both coronary and peripheral arteries, with numerous advantages over currently available devices
•Wrist-worn monitor that collects heart rate, skin, ambient temperature, movement tracking, and sleep data